Skip to main content
. Author manuscript; available in PMC: 2009 Aug 1.
Published in final edited form as: Mol Ther. 2008 Jun 10;16(8):1382–1391. doi: 10.1038/mt.2008.112

Figure 1. Treatment of human glioma cells with oncolytic virus (OV) increases their angiogenic potential.

Figure 1

(a) Images of individual angioreactors containing HSVQ-treated (top) or phosphate-buffered saline (PBS)-treated LN229 glioma cells at the time of harvesting. Briefly, angioreactors filled with LN229 glioma cells treated with either PBS or HSVQ (n = 9/group) were implanted subcutaneously in athymic nude mice. Fifteen days after implantation, the angioreactors were harvested and analyzed visually for blood vessels that had developed into the tubes. The presence of visually obvious initiation of blood vessels into six of the nine HSVQ-treated angioreactors and into one of the nine PBS-treated angioreactors are indicated by arrow heads. (b) Quantification of hemoglobin (Hb) in angioreactors treated with HSVQ or PBS. The contents of the individual angioreactors were isolated and the amount of Hb in each tube was quantified. Note the significantly higher values of Hb in angioreactors filled with HSVQ-treated LN229 cells as compared to values in angioreactors with PBS-treated LN229 cells (2.58 times higher, P < 0.021). HSV-1, herpes simplex virus 1.